Influenza Drugs: Zanamivir and Peramivir – Neuraminidase Inhibitors (Nursing)

00:00 Okay, still looking at the Neuraminidase Inhibitors, but we're going to look at Zanamivir.

00:06 Now it ends in "VIR", remember that's the clue about viruses.

00:10 But look at the slide got a great picture for you there.

00:14 I love that we've shown you what it looks like for this special unique powder inhaler.

00:19 That's why I've got the, besides shooting out there because this one is available.

00:24 IVPO inhalation powder.

00:27 You can also take it as a nebulizer or an intranasal.

00:30 So we've got a lot of options for taking it will talk about those in just a minute but here's good news for really tired students.

00:39 Look at the common adverse effects for both of these drugs.

00:42 Oseltamivir and you've got Zanamivir what's in common? Yeah.

00:47 Look at these two lists.

00:49 This most common adverse effects are the same just about all the way down, right? So you don't have to memorize these separately.

00:57 You chunk this information together and remind yourself whether it's Tamiflu.

01:02 And what's the generic? or it's relenza? And what's the generic? Right.

01:08 They have the most common adverse effects that most of your patients will experience are very similar.

01:15 Now, let's talk about the more intense side effects of the relenza.

01:19 You see we've got that inhalation powder got the name underneath it.

01:23 That's what it kind of looks like.

01:24 It's a very unique unit that you used for this inhalation powder.

01:29 But think about patients with lung risk.

01:32 So are talking about an inhalation powder.

01:35 It would make sense.

01:36 It'll be easier for you to remember.

01:38 Oh, somebody with lung problems.

01:40 This might be a problem.

01:42 So if they've got a potential higher risk for patients who have lung disease, so if a patient who's asthmatic think when they normally inhale things in I can be a little problematic for them.

01:52 Now if it's a bronchodilator, that's a good thing.

01:55 But if I taking an inhaled powder this might give us some more problems.

01:59 So it could cause a bronchospasm or some other respiratory challenges that would cause them to have what we call a respiratory decline that just means they're breathing is becoming more labored.

02:10 They're having problems.

02:11 They're not oxygenating as well.

02:14 That's what respiratory decline would be.

02:16 So somebody with lung problems takes these inhaled powders, they might cause a bronchospasm or respiratory decline.

02:23 Now some patients.

02:24 It's been kind of severe like they needed to be hospitalized in order to recover from from this.

02:29 But see here's the problem.

02:31 We're not really sure if the effect of needing to be hospitalized was because of the virus influenza virus or using the powder inhaler, but keep in mind somebody who uses a powder inhaler.

02:45 Hey, there's some cool things about that.

02:47 Maybe the patient has difficulty swallowing pills yours.

02:50 Not gonna have to be IV.

02:52 And another cool thing this is delivering the medication right to the site of the problem.

02:58 That's usually our preferred route because the more medication we can get right to the target, That's awesome for lots of reasons.

03:06 I get the medication to where it's needed.

03:09 You have less systemic side effects, but if I already have sensitive lungs, this could be problematic.

03:15 So we spent time on this just to help you keep in mind that this is an influenza infecting F impacting the respiratory system.

03:26 It's really cool to deliver a medication right to this part of the problem.

03:31 However, if they have difficulties with lungs already, this might not be the best choice to deliver it with this route.

03:38 So strongly consider another route if it's problematic for a patient to have an inhale route like this.

03:45 Okay, let's look at peramivir, again it ends in "VIR", so we know that it goes right? right against that virus, now this is an IV one so we don't see a lot of these given, in an outpatient typesetting and patients must be greater than 6 months of age.

04:01 We gave one dose over 30 to 60 minutes.

04:04 So technically this could be given right in an ER.

04:08 Now adverse effects most commonly, It's the GI effects.

04:11 I know we're giving it IV, but they can still end up with some kind of irritable GI stuff and up with diarrhea.

04:18 Now this is also rare that they'd have a hypersensitivity disorder, but it is a possibility.

04:23 Again common theme with with all these antivirals that we've discussed so far.